Exelixis, Inc. $EXEL Shares Sold by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. trimmed its stake in Exelixis, Inc. (NASDAQ:EXEL) by 3.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,037,698 shares of the biotechnology company’s stock after selling 74,235 shares during the period. Jupiter Asset Management Ltd.’s holdings in Exelixis were worth $89,312,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Farallon Capital Management LLC boosted its stake in Exelixis by 21.6% in the third quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock valued at $805,412,000 after acquiring an additional 3,466,000 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Exelixis by 20.7% during the third quarter. AQR Capital Management LLC now owns 9,181,359 shares of the biotechnology company’s stock worth $379,190,000 after purchasing an additional 1,575,280 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Exelixis by 7.1% in the 3rd quarter. Invesco Ltd. now owns 5,960,525 shares of the biotechnology company’s stock valued at $246,170,000 after purchasing an additional 394,897 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Exelixis by 11.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock valued at $172,658,000 after purchasing an additional 419,596 shares during the period. Finally, UBS Group AG boosted its position in shares of Exelixis by 40.2% in the 4th quarter. UBS Group AG now owns 3,722,334 shares of the biotechnology company’s stock valued at $163,150,000 after purchasing an additional 1,067,265 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on EXEL. Zacks Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 5th. Truist Financial upgraded shares of Exelixis to a “strong-buy” rating in a research report on Monday, April 27th. Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. TD Cowen increased their price target on shares of Exelixis from $51.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Exelixis presently has an average rating of “Hold” and a consensus target price of $47.35.

Exelixis Trading Up 2.8%

NASDAQ:EXEL opened at $51.45 on Friday. Exelixis, Inc. has a 12-month low of $33.76 and a 12-month high of $52.96. The stock’s 50 day simple moving average is $45.83 and its 200-day simple moving average is $44.18. The firm has a market cap of $12.93 billion, a P/E ratio of 17.09, a PEG ratio of 1.06 and a beta of 0.38.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm had revenue of $610.81 million for the quarter, compared to analyst estimates of $607.51 million. During the same period last year, the firm posted $0.55 EPS. Exelixis’s quarterly revenue was up 10.0% on a year-over-year basis. Research analysts forecast that Exelixis, Inc. will post 3.15 EPS for the current fiscal year.

Insider Buying and Selling

In other Exelixis news, EVP Dana Aftab sold 43,451 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $50.35, for a total transaction of $2,187,757.85. Following the transaction, the executive vice president owned 594,741 shares in the company, valued at approximately $29,945,209.35. The trade was a 6.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Christopher J. Senner sold 34,901 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $50.00, for a total value of $1,745,050.00. Following the completion of the sale, the chief financial officer directly owned 952,317 shares of the company’s stock, valued at $47,615,850. This represents a 3.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 205,433 shares of company stock worth $9,930,259 in the last three months. Company insiders own 2.60% of the company’s stock.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research raised its Q2 2026 EPS estimate for Exelixis to $0.75 from $0.72, reinforcing expectations that the company can continue delivering solid profitability.
• Positive Sentiment: Exelixis is set to participate in upcoming June investor conferences, which can help keep attention on the stock and provide new updates on pipeline and commercial progress. Article Title
• Positive Sentiment: A recent article argued that profitable, cash-generative biotech names like Exelixis may benefit as investors rotate away from expensive growth stocks and toward defensive healthcare ideas. Article Title
• Positive Sentiment: At the company’s annual meeting, investors backed the board, equity plan, and executive pay, signaling governance support and reducing uncertainty. Article Title
• Neutral Sentiment: Exelixis presented at Bernstein’s Strategic Decisions Conference, which keeps the company visible to institutional investors but did not include any major new operating update. Article Title
• Neutral Sentiment: A short-interest report showed essentially no short interest in Exelixis, suggesting limited bearish positioning but not a meaningful catalyst on its own.
• Negative Sentiment: EVP Dana Aftab sold 43,451 shares at an average price of $50.35, a disclosed insider sale that can weigh on sentiment even though the executive still holds a large position. Article Title

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.